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Pigs are often used as predictive models of nanomedicine-mediated cardiopulmonary distress reactions 
in humans. Unlike humans, pulmonary intravascular macrophages (PIM) are abundant in pig lungs. 
Robust phagocytosis of particles by PIM results in immediate release of large quantities of mediators that 
correlate with periods of peak cardiopulmonary disturbances. This raises questions on relevance of the 
pig model to human cases. However, there are suggestions of induction of pulmonary macrophages in 
certain human diseases (e.g., liver and inflammatory lung diseases). It is conceivable that highly 
responsive patients may have induced PIM, which could increase sensitivity to blood-borne particles, and 
the potential risk of pulmonary hemodynamic side effects. Accordingly, it would be necessary to search 
for constitutive or induced PIM in biopsied or autopsied human lungs, map their phenotype in liver and 
inflammatory lung diseases, and understand the pathologic implication of phagocyte residency in 
pulmonary capillaries. In this presentation, I will discuss the roles of PIM and the complement system 
activation on initiation of adverse cardiopulmonary distress on nanomedicine administration as well as 
simple strategies that could overcome these problems even in the pig model. Alternative animal models 
will be suggested for investigating the interplay between induced PIM and the complement system that 
could closely resemble the human cases and applicable for cardiopulmonary risk assessment in relation 
to biopharmaceuticals/nanomedicine administration.  
 
